RBC Capital lowered the firm’s price target on Chemed (CHE) to $572 from $589 and keeps an Outperform rating on the shares. The company reported solid Q3 results and reaffirmed full-year guidance, the analyst tells investors in a research note. While adjusted EBITDA in both VITAS and Roto-Rooter was slightly below Street consensus, the print was in line with the management’s expectations and serves as reaffirmation of its confidence in navigating challenges, RBC added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
- Chemed Reports Mixed Q3 2025 Earnings Performance
- Chemed’s Earnings Call: Growth Amid Challenges
- Chemed reiterates FY25 EPS guidance of $22.00-$22,30, consensus $22.15
- Chemed reports Q3 adjusted EPS $5.27, consensus $5.36
- These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 10/28/2025